Related Experiment Video
Updated: Aug 17, 2026
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Detection of somatic TP53 splice site mutations in diffuse astrocytomas
Miyuki Uno1, Sueli Mieko Oba-Shinjo, Paulo Henrique de Aguiar
1Department of Neurology, School of Medicine, University of São Paulo, Av. Dr Arnaldo 455, Cerqueira César, room 4110, 01246-903 São Paulo, SP, Brazil. unomiyuki@lim15.fm.usp.br
Abstract:
Alteration in TP53 is the most common genetic event reported for many tumors, including astrocytomas. The majority of studies, on analyzing TP53 mutations, have not included all splice junctions. Consequently, splice site mutations are thought to be relatively infrequent. TP53 were examined for mutations by polymerase chain reaction, single strand conformation polymorphism and direct sequencing in cases of diffuse astrocytomas. We found TP53 mutations in 17.8% (8 out of 45) of the tumors tested: 3 splicing, 3 missense and 2 silent mutations. We have shown that splice site mutations of TP53 are more frequent than previously reported. These findings emphasize the importance of thorough screening of TP53 mutations in gliomas.
Insights
TP53 mutations are common in astrocytomas, but splice site mutations are often missed. This study found these mutations are more frequent than previously thought, highlighting the need for thorough TP53 screening in gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- TP53 alterations are frequent in various cancers, including astrocytomas.
- Previous studies often overlooked splice junctions when analyzing TP53 mutations.
- This led to an underestimation of splice site mutation frequency.
Purpose of the Study:
- To investigate the frequency of TP53 mutations, particularly splice site mutations, in diffuse astrocytomas.
- To emphasize the importance of comprehensive TP53 mutation screening in glioma diagnosis and treatment.
Main Methods:
- Mutation analysis of the TP53 gene in 45 diffuse astrocytoma samples.
- Utilized polymerase chain reaction, single-strand conformation polymorphism, and direct sequencing.
- Included examination of all splice junctions for comprehensive analysis.
Main Results:
- TP53 mutations were identified in 17.8% (8 out of 45) of the tested astrocytoma samples.
- Specific findings included 3 splice site mutations, 3 missense mutations, and 2 silent mutations.
- The study revealed a higher incidence of TP53 splice site mutations than previously reported.
Conclusions:
- Splice site mutations in TP53 are more common in diffuse astrocytomas than previously recognized.
- Thorough screening of all TP53 mutations, including splice sites, is crucial for glioma research and clinical practice.
- These findings contribute to a better understanding of the genetic landscape of astrocytomas.
